-5%
Daprotab is used for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.
Daprotab is not recommended for:
- Patients requiring immediate correction of anemia as a substitute for red blood cell transfusions.
- Treatment of CKD-related anemia in patients not on dialysis.
Daprodustat is a hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI). It regulates HIF levels, a key transcription factor for genes involved in erythropoiesis. By reversibly inhibiting HIF-PH, Daprodustat:
✅ Increases plasma erythropoietin (EPO) levels.
✅ Regulates iron transport proteins.
✅ Reduces hepcidin (an iron-regulating protein elevated in CKD).
✅ Improves iron bioavailability and promotes red blood cell production.